As of current guidelines, GLP-1 receptor agonists including tirzepatide are not listed as disqualifying medications, though donors are advised to discuss their complete medical history with collection staff
March 2025 June 2025: Multi-district litigation saw rapid growth, jumping from 1,443 to 1,882 Ozempic cases, fueled by gastrointestinal injuries, gastroparesis, and intestinal obstruction claims
That premium reflects the specificity of the mechanism: tesamorelin is the only GHRH analog with direct FDA-validated evidence for visceral fat reduction
Key Takeaways Retatrutide is being studied as a triple agonist that targets GIP, GLP-1, and glucagon receptors
Woldeselassie M, Tamene A
(WDRB) -- A Louisville woman claims a popular weight loss drug she was prescribed for Type 2 diabetes almost killed her